Literature DB >> 22787160

Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.

Xu Zhang1, Zhuo Zhang, Jianwen Cheng, Mao Li, Wei Wang, Wenrong Xu, Hui Wang, Ruiwen Zhang.   

Abstract

Although the MDM2-p53 interaction has been well documented, MDM2 overexpression is observed in human cancers with little or no functional p53, suggesting that mdm2 expression is regulated by mechanisms independent of p53. Dysregulation of NFAT signaling is associated with malignant transformation and cancer development and progression. In this study, we demonstrate that the human mdm2 P2 promoter contains a consensus binding site for the NFAT1 transcription factor. NFAT1 directly binds the mdm2 P2 promoter in vitro and in vivo, resulting in the up-regulation of mdm2 transcription. Enforced expression of NFAT1 results in an elevated MDM2 protein level and reduces p53 activation and function in response to DNA damage. Both NFAT1 and MDM2 are highly expressed in human hepatocellular carcinoma tissues, compared with adjacent normal liver tissues. There is a positive correlation between the NFAT1 and MDM2 levels in tumor tissues. The novel function of NFAT1 in the control of MDM2 expression provides a basis for future investigations of the role of NFAT1 in cancer development, progression, and therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787160      PMCID: PMC3436296          DOI: 10.1074/jbc.M112.373738

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway.

Authors:  Malte Buchholz; Alexandra Schatz; Martin Wagner; Patrick Michl; Thomas Linhart; Guido Adler; Thomas M Gress; Volker Ellenrieder
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

2.  Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.

Authors:  Sandra Ryeom; Kwan-Hyuck Baek; Matthew J Rioth; Ryan C Lynch; Alexander Zaslavsky; Amy Birsner; Sam S Yoon; Frank McKeon
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

3.  NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2.

Authors:  Gary K Yiu; Alex Toker
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

4.  Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.

Authors:  Mao Li; Zhuo Zhang; Donald L Hill; Xinbin Chen; Hui Wang; Ruiwen Zhang
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

5.  Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.

Authors:  Mao Li; Zhuo Zhang; Donald L Hill; Hui Wang; Ruiwen Zhang
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

6.  Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection.

Authors:  Guo-Huan Yang; Jia Fan; Yang Xu; Shuang-Jian Qiu; Xin-Rong Yang; Guo-Ming Shi; Bing Wu; Zhi Dai; Yin-Kun Liu; Zhao-You Tang; Jian Zhou
Journal:  Oncologist       Date:  2008-11-07

7.  Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells.

Authors:  Amel Chebel; Jean-Pierre Rouault; Iwona Urbanowicz; Lucile Baseggio; Wei-Wen Chien; Gilles Salles; Martine Ffrench
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 8.  NFAT proteins: emerging roles in cancer progression.

Authors:  Maria Mancini; Alex Toker
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.

Authors:  Joachim H Maxeiner; Roman Karwot; Kerstin Sauer; Petra Scholtes; Ildiko Boross; Michael Koslowski; Ozlem Türeci; Rainer Wiewrodt; Markus F Neurath; Hans A Lehr; Susetta Finotto
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

10.  Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.

Authors:  Hind Medyouf; Hélène Alcalde; Caroline Berthier; Marie Claude Guillemin; Nuno R dos Santos; Anne Janin; Didier Decaudin; Hugues de Thé; Jacques Ghysdael
Journal:  Nat Med       Date:  2007-05-21       Impact factor: 53.440

View more
  24 in total

Review 1.  p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Authors:  Howard B Lieberman; Sunil K Panigrahi; Kevin M Hopkins; Li Wang; Constantinos G Broustas
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

2.  Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Bhavitavya Nijampatnam; Sadanandan E Velu; Ke-He Ruan; Ming Hu; Jianwei Zhou; Ruiwen Zhang
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

Review 3.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

4.  MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.

Authors:  Wei Wang; Jian-Wen Cheng; Jiang-Jiang Qin; Bo Hu; Xin Li; Bhavitavya Nijampatnam; Sadanandan E Velu; Jia Fan; Xin-Rong Yang; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2019-06-07       Impact factor: 8.679

Review 5.  The regulation of MDM2 oncogene and its impact on human cancers.

Authors:  Yuhan Zhao; Haiyang Yu; Wenwei Hu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2014-01-03       Impact factor: 3.848

6.  The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Kalkunte S Srivenugopal; Subhasree Nag; Shivaputra Patil; Horrick Sharma; Ming-Hai Wang; Hui Wang; John K Buolamwini; Ruiwen Zhang
Journal:  Nat Commun       Date:  2014-10-01       Impact factor: 14.919

7.  The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.

Authors:  Hang Li; Qian Liu; Zhen Wang; Runping Fang; Yu Shen; Xiaoli Cai; Yuen Gao; Yinghui Li; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

8.  Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Authors:  Benjamin Gottschalk; Andreas Klein
Journal:  Mol Cell Biochem       Date:  2013-04-07       Impact factor: 3.396

Review 9.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

10.  Epithelial calcineurin controls microbiota-dependent intestinal tumor development.

Authors:  Kenneth Peuker; Stefanie Muff; Jun Wang; Sven Künzel; Esther Bosse; Yvonne Zeissig; Giuseppina Luzzi; Marijana Basic; Anne Strigli; Andrea Ulbricht; Arthur Kaser; Alexander Arlt; Triantafyllos Chavakis; Gijs R van den Brink; Clemens Schafmayer; Jan-Hendrik Egberts; Thomas Becker; Marco E Bianchi; André Bleich; Christoph Röcken; Jochen Hampe; Stefan Schreiber; John F Baines; Richard S Blumberg; Sebastian Zeissig
Journal:  Nat Med       Date:  2016-04-04       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.